Comment on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials

Lung Cancer. 2018 Dec:126:224. doi: 10.1016/j.lungcan.2018.09.003. Epub 2018 Sep 7.

Authors

Ran Xu¹, Jing Zhu²

Affiliations

¹ Medical School of Nantong University, Jiangsu, 226001, China.
² The Affiliated Huaian NO.1 People's Hospital of Nanjing Medical University, Jiangsu, 223001, China. Electronic address: cellbiology@126.com.

PMID: 30217601
DOI: 10.1016/j.lungcan.2018.09.003

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Carcinoma, Non-Small-Cell Lung*
Erlotinib Hydrochloride
Humans
Lung Neoplasms*
Randomized Controlled Trials as Topic

Substances

Bevacizumab
Erlotinib Hydrochloride